Another week, another round of developments across psychedelic medicine. Below is our recap of what mattered to investors for the week of August 18–24, 2025.
Reunion Neuroscience (—): Reunion's RE104 hits primary endpoint in Phase 2 RECONNECT postpartum-depression trial
Reunion Neuroscience reported positive topline results from its Phase 2 RECONNECT trial of RE104 in postpartum depression, with a single 30 mg subcutaneous dose producing a 23.0-point MADRS reduction at Day 7 versus 17.2 points for the 1.5 mg active control (p=0.0094). Response rate was 77.1% for the 30 mg arm versus 61.6% for control, with effects maintained through Day 28 across 84 patients at 38 US sites. The clean win in a fast-acting, shorter-duration psychedelic strengthens the private company's differentiated late-stage prospects.
Source: globenewswire.com
Cybin Inc. (CYBN): Cybin shareholders approve full board slate and auditor at annual meeting
Cybin held its annual general meeting in Toronto on August 18, 2025, with holders of about 11.26 million shares (roughly 49% of shares outstanding) represented. Shareholders elected all director nominees and reappointed Zeifmans LLP as auditor. The routine governance vote followed the company's fiscal Q1 2026 report detailing a $50 million convertible financing and $118.7 million in cash.
Source: finance.yahoo.com
That's the recap. Follow the Psychedelic Invest Index for how the sector is trading, and check back next week for the next edition.